Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 13, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Reply: To PMID 25370956

M Margarida Souto-Carneiro1,2, Hanns-Martin Lorenz2

  • 1University of Coimbra, Coimbra, Portugal.

Arthritis & Rheumatology (Hoboken, N.J.)
|May 6, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
05:51

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

Published on: March 17, 2023

2.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Related Experiment Videos

Last Updated: Apr 13, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K
A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
05:51

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

Published on: March 17, 2023

2.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.

Science translational medicine·2026
Same author

Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.

Nature medicine·2026
Same author

A deep learning-based computational pipeline predicts developmental outcome in retinal organoids.

PLoS biology·2026
Same author

Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis.

Journal of innate immunity·2025
Same author

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.

Rheumatology (Oxford, England)·2025